A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.
